Cidara Therapeutics is a US-based biotech company that develops and commercializes anti-infectives for treating infectious diseases and oncology. The company’s lead product candidate is rezafungin acetate, a novel antifungal molecule that treats and prevents invasive fungal infections such as candidemia. The company also advances its Cloudbreak platform to develop conjugates for treating other viral infections such as RSV, HIV, and the strains causing COVID-19.